Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months
Regina Hodits from Angelini Ventures to join Rouge Therapeutics’ Board of Directors
Rome, Italy, 6 October 2026 – Angelini Ventures, the venture arm of Angelini Industries focused on investing globally in companies developing innovative solutions in BioTech and HealthTech, today announces it has co-led a $58 million Series A financing in Rouge Therapeutics, a preclinical-stage biotechnology company developing potential first-in-class, disease-modifying therapies for rare vascular diseases.
The financing was co-led by Angelini Ventures, with support from the European Investment Bank (EIB) via Angelini Ventures’ Aurea co-investment vehicle, alongside co-lead investors BioGeneration Ventures (BGV) and Kurma Partners. Epidarex Capital, Vesalius Biocapital Partners, ROM-Utrecht Region, p53 Invest and Kerna Ventures also participated in the round.
This financing marks the fourth co-investment completed by Angelini Ventures and the EIB in less than 12 months under their €150 million partnership, which was established in December 2025 to support European companies developing innovative solutions across biotechnology, medtech and digital health.
Proceeds from the fundraise will be used to support RougeTx’s lead program, RTX-001 as it advances toward first-in-human clinical development for hereditary hemorrhagic telangiectasia (HHT). HHT is the second most common inherited bleeding disorder. The disease is caused by abnormal blood vessel formation known as arteriovenous malformations (AVMs), which can lead to recurrent nose and gastrointestinal bleeding, iron deficiency, chronic anemia, and potentially serious complications affecting major organs. There are currently no approved therapies for HHT, and patients rely largely on supportive care and off-label treatments.
Regina Hodits, Managing Director of Angelini Ventures will join the Rouge Therapeutics Board of Directors.
“RougeTx is taking an innovative and highly differentiated approach to vascular disease by focusing on the critical role of pericytes in maintaining blood vessel stability, this is very different to other treatment paradigms in the field,” said Regina Hodits, Managing Director of Angelini Ventures. “RTX-001 has the potential to provide a new treatment option for people living with HHT, while exploiting the novel underlying biology opens up opportunities in other diseases marked by vascular instability.
“The strength of the science and the team’s execution have reinforced our conviction in the approach, and we are excited to support the company as it advances towards clinical development. This investment reflects our increased focus on our company building strategy, backing high-potential science and strong founder teams. Angelini Ventures will actively support these companies on their journey to becoming global leaders.”
***
Notes to Editors
About Rouge Therapeutics
Rouge Tx is a spin-off from Leiden University Medical Center (LUMC) and is developing first-in-
class small-molecule therapies to restore vascular stability in diseases driven by pericyte
dysfunction. Pericytes regulate angiogenesis and support blood vessel integrity and function.
Our aim is to move beyond current symptom management toward urgently needed disease-
modifying treatments for vascular diseases. Our lead program targets Hereditary Hemorrhagic Telangiectasia (HHT) along with additional indications related to vascular stability diseases.
www.rougetx.com
About Angelini Ventures
Angelini Ventures is an international venture capital company and part of Angelini Industries, an Italian industrial group working in health, industrial technology and consumer goods. Angelini Ventures was formed in 2022 with a commitment of €375 million, about €125 million of which have already been allocated to startups developing innovative solutions and ideas in biotechnology, medtech and digital health. It invests in innovative companies in Europe and North America that can improve patients’ life expectancy and quality of life. The company is based in Rome and has a global team of 24 professionals working in thirteen cities (Rome, Milan, Turin, London, Singapore, Boston, Berlin, Copenhagen, Geneva, New York, Munich, Basel and Paris). Angelini Ventures is part of Angelini Industries’ strategy to promote innovation by combining existing capabilities and new skills to identify, finance and implement solutions that innovate on traditional healthcare models. To date, Angelini Ventures has invested into 25+ companies covering a range of therapeutic areas and modalities.
www.angeliniventures.com
Contacts
Angelini Ventures
Martina Palmese, Brand & Communications Manager
martina.palmese@angeliniventures.com
Media contacts outside Italy – MEDiSTRAVA
Sylvie Berrebi, Sandi Greenwood, Mark Swallow
angeliniventures@medistrava.com
Media contacts for Italy – SEC Newgate Italia
Daniele Pinosa, daniele.pinosa@secnewgate.it; Tel. +39 3357233872
Fausta Tagliarini; fausta.tagliarini@secnewgate.it; Tel. +39 3476474513
Daniele Murgia; daniele.murgia@secnewgate.it; Tel. +39 3384330031
Attachment
